SLNSW-Switching to coformulated elvitegravir, cobicista...-TN_cdi_proquest_miscellaneous_1551626997

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Full title: Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Author/creator: Pozniak, Anton, Dr, Markowitz, Martin, Prof, Mills, Anthony, MD, Stellbrink, Hans-Juergen, MD, Antela, Antonio, MD, Domingo, Pere, Prof, Girard, Pierre-Marie, MD, Henry, Keith, Prof, Nguyen, Thai, MD, Piontkowsky, David, MD, Garner, Will, PhD, White, Kirsten, PhD, Guyer, Bill, PharmD.

Call Numbers:

Record Identifier: TN_cdi_proquest_miscellaneous_1551626997

Language: English

Formats: Articles

Publishers: London: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1551626997

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

    Record identifier

    TN_cdi_proquest_miscellaneous_1551626997

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1551626997

    Share

    Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1551626997

    Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

    Full title

    Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

    Author / Creator

    Pozniak, Anton, Dr ; Markowitz, Martin, Prof ; Mills, Anthony, MD ; Stellbrink, Hans-Juergen, MD ; Antela, Antonio, MD ; Domingo, Pere, Prof ; Girard, Pierre-Marie, MD ; Henry, Keith, Prof ; Nguyen, Thai, MD ; Piontkowsky, David, MD ; Garner, Will, PhD ; White, Kirsten, PhD ; Guyer, Bill, PharmD

    Publisher

    London: Elsevier Ltd

    Journal title

    The Lancet infectious diseases, 2014, Vol.14 (7), p.590-599

    Record Identifier

    TN_cdi_proquest_miscellaneous_1551626997

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adenine - analogs & derivatives Adenine - therapeutic use Adult Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antiviral agents Biological and medical sciences Carbamates - therapeutic use Cobicistat Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use DNA polymerases Drug therapy Emtricitabine Female Genotype & phenotype HIV HIV Infections - drug therapy Human immunodeficiency virus Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious Disease Infectious diseases Insomnia Male Medical sciences Middle Aged Nucleosides Organophosphonates - therapeutic use Pharmacology. Drug treatments Plasma Population Quinolones - therapeutic use Reverse Transcriptase Inhibitors - therapeutic use Statistical analysis Tenofovir Thiazoles - therapeutic use Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load - drug effects

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_miscellaneous_1551626997

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1551626997

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    About resource >

    View in old catalogue

    Connecting people and collections